

huVEGFR1 D2-D3 DTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIP
cynVEGFR1 D2-D3 ----------I----------
ratVEGFR1 D2-D3 -A-S--I--H-D--KLV---------I----------F-A-T-
mouVEGFR1 D2-D3 -A-S--I--HTD--KLV---------Q-I----------F---T-
RabVEGFR1 D2-D3 -ADK-----T----VLY-H----------N-----Q--S-QV--
ChiVEGFR1 D2-D3 --SN-----H-D--K-----V-K-MI---------A---A-----I-RE-----
huVEGFR1 D2-D3 DGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTI
cynVEGFR1 D2-D3 ----V----------
ratVEGFR1 D2-D3 --Q--A-----R-----A----------Q-S----------
mouVEGFR1 D2-D3 --Q--T-----R-----A----------Q----------
RabVEGFR1 D2-D3 H-E--T-N--R---V-S---------I-Y---S---QV---H--I--L-----
ChiVEGFR1 D2-D3 ---T----NMR--R-PE---RF-----S--T-IG--K-S-K-----E-----
huVEGFR1 D2-D3 IDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVR
cynVEGFR1 D2-D3 ----------I----------
ratVEGFR1 D2-D3 L-----P-S--RF---Q---------V--D---------S-N--GKAT-----I-
mouVEGFR1 D2-D3 L-----RP-S--R--H-Q---------E---------S-N--GKAT-----I-
RabVEGFR1 D2-D3 L---M---S-----K-RA-N----------GQTS-------
ChiVEGFR1 D2-D3 F-IKL-----L-----K-DS-AI---VKAAW---------T--G-AM--G--T
huVEGFR1 D2-D3 RRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDK
cynVEGFR1 D2-D3 ----------V----------
ratVEGFR1 D2-D3 Q-------P-S-V-H---K-NNVESR----------K--S--RTF-----V-E-
mouVEGFR1 D2-D3 QQ---R-H--N-V-H---K-NNVESR----------K--S--Q-F-----V-E-
RabVEGFR1 D2-D3 QQ-------SA-----V---------QV--R----------Q-K-------R-AS-----V-----
ChiVEGFR1 D2-D3 Q-----K-RE--V---I-V---VRDI---Q-A-H-K-----N-L---T-IV-----

FIG. 1



HuVEGFR1 (HEK)
CyVEGFR1 (HEK)
MoVEGFR1 (HEK)
HuVEGFR2 (HEK)
HuVEGFR3 (K562)
Parental (K562)
Cell Binding (MFI)
10000
5000
0
Background
45427p1.D8 (VGFB54)
45427p3.A6 (VGFB71)
45427p3.H12 (VGFB78)
45462p2.1.A7 (VGFB82)

FIG. 2



Chothia H105
Relative Frequency (%)
0
20
40
60
80
A C D E F G H I K L M N P Q R S T V W Y -

FIG. 3



Free Energy
Change (kcal/mol)
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
n.d. too slow
VGFB54
VGFB71
VGFB78
VGFB82

FIG. 4A



Free Energy
Change (kcal/mol)
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
n.d. too slow
VGFB54
VGFB71
VGFB78
VGFB82

FIG. 4B



VGFB54
10 mg/kg - Total drug
2 mg/kg - Total drug
0.3 mg/kg - Total drug
LLOQ - Total drug assay
10 mg/kg - Free drug
2 mg/kg - Free drug
0.3 mg/kg - Free drug
LLOQ - Free drug assay
Concentration (ng/mL)
1000000
100000
10000
1000
100
10
1
Time (days)
0
5
10
15
20
25
30

FIG. 5



VGFB78
10 mg/kg - Total drug
2 mg/kg - Total drug
0.3 mg/kg - Total drug
LLOQ-Total
10 mg/kg - Free
2 mg/kg - Free drug
0.3 mg/kg - Free drug
LLOQ-Free
Concentration (ng/mL)
1000000
100000
10000
1000
100
10
1
Time (days)
0
5
10
15
20
25
30

FIG. 6



VGFB82
10 mg/kg - Total drug
2 mg/kg - Total drug
0.3 mg/kg - Total drug
LLOQ - Total drug assay
10 mg/kg - Free drug
2 mg/kg - Free drug
0.3 mg/kg - Free drug
LLOQ - Free drug assay
Concentration (ng/mL)
1000000
100000
10000
1000
100
10
1
Time (Days)
0
5
10
15
20
25
30

FIG. 7



VGFB 80
10 mg/kg - Total drug
2 mg/kg - Total drug
0.3 mg/kg - Total drug
LLOQ - Total drug assay
10 mg/kg - Free drug
2 mg/kg - Free drug
0.3 mg/kg - Free drug
LLOQ - Free drug assay
Concentration (ng/mL)
Time (days)

FIG. 8



VGFB54
Plasma PIGF
0.3 mg/kg
2 mg/kg
10 mg/kg
PlGF Concentration (pg/mL)
5000
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Time (days)

FIG. 9



VGFB78
Plasma PlGF
0.3 mg/kg
2 mg/kg
10 mg/kg
PlGF Concentration (pg/mL)
5000
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Time (days)

FIG. 10



VGFB82
Plasma PlGF
0.3 mg/kg
2 mg/kg
10 mg/kg
PlGF Concentration (pg/mL)
5000
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Time (days)

FIG. 11



VGFB80
Plasma PlGF
0.3 mg/kg
2 mg/kg
10 mg/kg
PlGF Concentration (pg/mL)
5000
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Time (days)

FIG. 12